Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CUE

CUE - Cue Biopharma Inc Stock Price, Fair Value and News

1.55USD+0.05 (+3.33%)Market Closed

Market Summary

CUE
USD1.55+0.05
Market Closed
3.33%

CUE Stock Price

View Fullscreen

CUE RSI Chart

CUE Valuation

Market Cap

75.4M

Price/Earnings (Trailing)

-1.51

Price/Sales (Trailing)

10.74

EV/EBITDA

-1.04

Price/Free Cashflow

-1.93

CUE Price/Sales (Trailing)

CUE Profitability

EBT Margin

-755.13%

Return on Equity

-166.36%

Return on Assets

-92.62%

Free Cashflow Yield

-51.68%

CUE Fundamentals

CUE Revenue

Revenue (TTM)

7.0M

Rev. Growth (Yr)

818.18%

Rev. Growth (Qtr)

-5.71%

CUE Earnings

Earnings (TTM)

-50.0M

Earnings Growth (Yr)

5.81%

Earnings Growth (Qtr)

8.09%

Breaking Down CUE Revenue

Last 7 days

-4.3%

Last 90 days

-25.1%

Trailing 12 Months

-59.0%

How does CUE drawdown profile look like?

CUE Financial Health

Current Ratio

2.47

Debt/Equity

0.11

Debt/Cashflow

-12

CUE Investor Care

Shares Dilution (1Y)

12.66%

Diluted EPS (TTM)

-1.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20247.0M000
2023432.0K1.8M3.8M5.5M
202214.4M11.7M9.3M1.2M
20213.8M5.5M7.2M14.9M
20204.0M4.0M3.7M3.2M
20191.7M2.3M2.9M3.5M
20180001.1M

Tracking the Latest Insider Buys and Sells of Cue Biopharma Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Aug 25, 2023
suri anish
bought
11,040
2.76
4,000
president and cso
Aug 14, 2023
passeri daniel r
bought
8,580
2.86
3,000
chief executive officer
Mar 23, 2023
kiener peter a
sold
-30,586
3.28
-9,325
-
Mar 23, 2023
kiener peter a
acquired
27,690
2.86
9,682
-
Aug 22, 2022
millar kerri-ann
sold (taxes)
-8,625
3.05
-2,828
chief financial officer
Aug 21, 2022
millar kerri-ann
acquired
-
-
6,667
chief financial officer
Jun 14, 2022
gray cameron
acquired
165,000
2.7
61,111
-
Jun 14, 2022
gray cameron
sold (taxes)
-164,998
3.2
-51,562
-
May 27, 2022
morich frank
bought
105,000
3.75
28,000
-
May 24, 2022
fletcher aaron g.l.
bought
183,700
3.34
55,000
-

1–10 of 50

Which funds bought or sold CUE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
COMERICA BANK
added
37.47
-62.00
3,827
-%
May 16, 2024
Tidal Investments LLC
new
-
21,947
21,947
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-144,220
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-8,799
6,838
-%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
sold off
-100
-58,978
-
-%
May 15, 2024
DEUTSCHE BANK AG\
unchanged
-
-22,350
56,324
-%
May 15, 2024
STATE STREET CORP
added
11.13
-368,942
1,436,010
-%
May 15, 2024
MORGAN STANLEY
reduced
-9.00
-151,558
283,266
-%
May 15, 2024
PRICE T ROWE ASSOCIATES INC /MD/
sold off
-100
-49,000
-
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-8.49
-242,406
460,434
-%

1–10 of 46

Are Funds Buying or Selling CUE?

Are funds buying CUE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CUE
No. of Funds

Unveiling Cue Biopharma Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
bleichroeder lp
6.11%
2,755,028
SC 13G
Feb 07, 2024
blackrock inc.
4.98%
2,247,978
SC 13G
Jan 31, 2024
blackrock inc.
5.2%
2,338,765
SC 13G
Feb 14, 2023
slate path capital lp
5.6%
2,402,455
SC 13G
Feb 03, 2023
state street corp
0.33%
141,153
SC 13G/A
Dec 02, 2022
nantahala capital management, llc
0.3%
93,297
SC 13G/A
Nov 18, 2022
slate path capital lp
5.6%
2,402,455
SC 13G
Jul 08, 2022
blackrock inc.
2.4%
831,925
SC 13G
Feb 14, 2022
nantahala capital management, llc
8.0%
2,539,700
SC 13G/A
Feb 14, 2022
corriente advisors, llc
0.0%
0
SC 13G/A

Recent SEC filings of Cue Biopharma Inc

View All Filings
Date Filed Form Type Document
Jun 07, 2024
3
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
8-K
Current Report
May 24, 2024
DEFA14A
DEFA14A
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report

Peers (Alternatives to Cue Biopharma Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Cue Biopharma Inc News

Latest updates
TipRanks07 Jun 202409:19 pm

Cue Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-5.7%1,717,0001,821,0002,100,0001,382,000187,000151,00068,00026,0001,000,0008,254,3702,395,0002,739,0001,553,000475,325704,0001,075,000900,0001,049,331984,0001,055,000370,000
Operating Expenses-8.1%14,385,00015,653,50013,519,00014,899,00013,567,00015,017,00011,099,00013,116,00015,238,00016,137,44315,413,00013,042,00014,071,00011,449,91010,835,00012,017,00013,895,00010,065,5788,078,00010,286,00011,797,000
  S&GA Expenses-9.2%4,186,0004,609,5003,645,0004,249,0004,176,0003,703,5003,528,0003,782,0005,156,0004,646,6784,125,0004,280,0004,255,0003,446,2053,318,0003,898,0003,989,0003,100,5932,776,0003,419,0003,444,000
  R&D Expenses-6.3%10,199,00010,887,0009,874,00010,650,0009,391,00011,332,5007,571,0009,592,00010,082,00011,490,76511,288,0008,762,0009,816,0008,003,7057,517,0008,119,0009,906,0006,964,9855,302,0006,867,0008,353,000
EBITDA Margin21.9%-7.65-9.79-14.03-29.85-123-42.41-4.60-3.66-2.95-2.84-----------
Interest Expenses44.2%-241,000-432,000-286,000-232,000-370,000-358,000-124,000-206,000-25,000------------
Income Taxes----------289,000--206,000-----500-413,000-
Earnings Before Taxes---------------10,896,671-10,031,000-10,833,000--8,918,457-6,990,000-9,109,000-
EBT Margin21.8%-7.55-9.66-13.88-29.65-122-42.58-4.67-3.74-3.03-2.92-5.68-7.43---------
Net Income8.1%-12,347,000-13,434,000-11,005,000-13,185,000-13,109,000-14,592,000-10,955,000-13,208,000-14,255,000-8,384,175-12,993,000-10,279,000-12,505,000-11,102,921-10,031,000-10,833,000-12,818,000-8,918,457-6,990,000-9,522,000-11,267,000
Net Income Margin23.0%-7.12-9.24-13.58-28.99-120-42.58-5.01-4.18-3.19-2.96-6.55-8.03---------
Free Cashflow10.2%-9,839,000-10,958,000-7,799,000-10,371,000-10,833,000-10,515,000-6,949,000-12,913,000-11,600,000-10,645,205-6,640,000-10,022,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-12.3%54.0062.0069.0073.0082.0091.0076.0085.0091.0083.0079.0090.0089.0010010710161.0072.0045.0042.0045.00
  Current Assets-13.2%45.0051.0058.0061.0069.0077.0062.0069.0076.0068.0070.0080.0077.0088.0094.0088.0051.0061.0033.0030.0032.00
    Cash Equivalents-15.4%41.0049.0055.0053.0056.0052.0030.0066.0068.0064.0068.0074.0073.0075.0072.0060.0023.0044.0031.0024.0022.00
  Net PPE-5.2%1.001.001.001.001.001.002.002.002.002.002.003.003.002.002.002.002.002.002.002.003.00
Liabilities-2.2%24.0024.0026.0027.0027.0026.0026.0025.0026.0018.0015.0017.0019.0021.0019.0021.0015.0017.0018.0021.0020.00
  Current Liabilities5.9%18.0017.0017.0016.0014.0012.0010.008.0011.0013.0015.0017.0017.0016.0014.0015.0012.0012.0010.0011.0011.00
  Long Term Debt-22.8%3.004.005.006.007.008.009.0010.0010.00------------
    LT Debt, Non Current-22.8%3.004.005.006.007.008.009.0010.0010.00------------
Shareholder's Equity-19.0%30.0037.0043.0046.0055.0066.0051.0060.0065.0065.0064.0073.0070.0079.0088.0080.0045.0055.0027.0020.0025.00
  Retained Earnings-4.1%-313-301-287-276-263-250-235-224-211-197-189-176-165-153-142-132-121-108-99.58-92.59-83.07
  Additional Paid-In Capital1.6%344338330323319316287285276263253249235232230212166163127113108
Shares Outstanding3.0%49.0047.0045.0044.0045.0047.0034.0034.0033.0032.0031.0031.00---------
Float----154---82.00---363---695---160-
Cashflow (Last 12 Months)
(In )
Cashflow (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations10.7%-9,784,000-10,958,000-7,799,000-10,371,000-10,833,000-10,514,000-6,871,000-12,848,000-11,573,000-10,645,166-6,627,000-9,770,000-11,795,000-6,999,034-7,687,000-6,864,000-10,944,000-6,437,910-9,208,000-6,676,000-8,475,000
  Share Based Compensation-6.1%1,946,0002,072,0002,073,0002,037,0001,998,0002,112,0002,064,0002,309,0003,011,0002,974,0843,252,0002,854,0002,436,0002,281,7822,500,0002,524,0003,175,0001,994,4821,439,0001,321,0001,768,000
Cashflow From Investing-Infinity%-55,000-5,000,0005,000,00015,002,0004,999,000-29,520,000-62,000-27,000511-11,000-233,0009,352,0009,891,8744,654,000-140,000-9,950,000-15,145,1773,984,0005,127,0009,481,000
Cashflow From Financing-50.8%2,354,0004,782,0004,589,0002,101,000388,00027,403,000-9,00011,109,00015,156,0007,382,322351,00010,666,000834,000244,26315,013,00043,321,00036,00034,493,76512,292,0003,747,000257,000
  Buy Backs-------9,000-191,000183,128482,000-85,000160,05135,000------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CUE Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Collaboration revenue$ 1,717$ 187
Operating expenses:  
General and administrative4,1864,176
Research and development10,1999,391
Total operating expenses14,38513,567
Loss from operations(12,668)(13,380)
Other income (expense):  
Interest income562641
Interest expense(241)(370)
Total other income (expense), net321271
Net loss(12,347)(13,109)
Unrealized gain from available-for-sale securities057
Comprehensive loss$ (12,347)$ (13,052)
Net loss per common share, basic$ (0.25)$ (0.29)
Net loss per common share, diluted$ (0.25)$ (0.29)
Weighted average common shares outstanding, basic49,466,71144,652,353
Weighted average common shares outstanding, diluted49,466,71144,652,353

CUE Balance Sheet

2024-03-31
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 41,029$ 48,514
Accounts receivable1,4001,698
Prepaid expenses and other current assets2,2401,242
Total current assets44,66951,454
Property and equipment, net754795
Operating lease right-of-use5,5736,323
Deposits2,6902,690
Restricted cash151151
Other long-term assets114117
Total assets53,95161,530
Current liabilities:  
Accounts payable3,9193,501
Accrued expenses5,2084,137
Research and development contract liability, current portion1,7902,112
Operating lease liabilities, current3,210 
Current portion of long-term debt, net3,9633,963
Total current liabilities18,09017,081
Operating lease liabilities, non-current2,579 
Long-term debt, net3,2444,202
Total liabilities23,91324,445
Commitments and contingencies (Note 11)
Stockholders' equity:  
Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.001 par value; 100,000,000 shares authorized; 48,643,316 and 47,215,116 shares issued and outstanding, at March 31, 2024 and December 31, 2023, respectively4847
Additional paid in capital343,527338,228
Accumulated deficit(313,537)(301,190)
Total stockholders' equity30,03837,085
Total liabilities and stockholders' equity$ 53,951$ 61,530
CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEcuebiopharma.com
 INDUSTRYBiotechnology
 EMPLOYEES51

Cue Biopharma Inc Frequently Asked Questions


What is the ticker symbol for Cue Biopharma Inc? What does CUE stand for in stocks?

CUE is the stock ticker symbol of Cue Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cue Biopharma Inc (CUE)?

As of Thu Jun 13 2024, market cap of Cue Biopharma Inc is 75.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CUE stock?

You can check CUE's fair value in chart for subscribers.

What is the fair value of CUE stock?

You can check CUE's fair value in chart for subscribers. The fair value of Cue Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cue Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CUE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cue Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether CUE is over valued or under valued. Whether Cue Biopharma Inc is cheap or expensive depends on the assumptions which impact Cue Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CUE.

What is Cue Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, CUE's PE ratio (Price to Earnings) is -1.51 and Price to Sales (PS) ratio is 10.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CUE PE ratio will change depending on the future growth rate expectations of investors.